MedTech Atlas
Back to medical device regulatory guideAll countries
EuropeENPublic regulatory overview

European Union (EU)

Market Overview Population: Approximately 450 million (EU27 member states, 2024); one of Europe's and the world's largest unified medical device markets Healthcare system: Each mem...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRCore / local basis

CE marking under the applicable EU framework is the primary conformity route.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingDossier reuse only

The NMPA certificate itself has limited effect, but ISO/IEC-aligned test reports, clinical evidence, risk files, and PMS data can be reused after gap assessment.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: European Union (EU)
  • Product line: Medical devices
  • Regulator / source: Regulatory maturity: Very high. The EU is one of the world's most complex and stringent regulatory jurisdictions for medical devices. EU MDR 2017/745, which became fully applicable in 2021, represents a major tightening of EU regulation, with significantly elevated requirements for technical documentation, clinical evidence, and post-market surveillance. The dramatic reduction in Notified Body (NB) numbers has created a serious capacity bottleneck — currently the most prominent market access barrier.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Note: Classification rules are detailed in MDR Annex VIII (medical devices) and IVDR Annex VIII (IVDs). Classification disputes may be submitted to member state CAs for a ruling. The classification decision has a decisive impact on all subsequent compliance costs and timelines; a professional classification analysis is strongly recommended early in the project.
  • Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
  • Local requirement: MDR Article 11: Authorized Representative (EU AR) requirements — core compliance obligation for non-EU manufacturers
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Population: Approximately 450 million (EU27 member states, 2024); one of Europe's and the world's largest unified medical device markets
  • Healthcare system: Each member state manages its own national healthcare system, but the overall structure is a universal public health insurance/healthcare service framework. Germany (statutory health insurance, GKV), France (Sécurité Sociale), Italy (SSN), and Spain (SNS) all operate mandatory social insurance systems; Nordic countries operate predominantly tax-funded public healthcare.
  • Market size: The EU medical device market is approximately EUR 140 billion per year (2023), accounting for ~27% of the global medical device market and ranking as the world's second-largest market (after the US). Germany, France, Italy, Spain, and the Netherlands are the top five sub-markets. Germany alone is the largest European single-country market at approximately EUR 30 billion per year.
  • Market characteristics: The unified CE marking system theoretically allows a single certification to access all 27 EU member state markets. In practice, however, market access (procurement and reimbursement) is highly fragmented — national Health Technology Assessment (HTA), pricing, and reimbursement policies vary enormously. High-end and innovative products are concentrated in Germany, France, the Netherlands, and the Nordic markets. Southern Europe (Italy, Spain) public hospital procurement is dominated by price competition.
  • Regulatory maturity: Very high. The EU is one of the world's most complex and stringent regulatory jurisdictions for medical devices. EU MDR 2017/745, which became fully applicable in 2021, represents a major tightening of EU regulation, with significantly elevated requirements for technical documentation, clinical evidence, and post-market surveillance. The dramatic reduction in Notified Body (NB) numbers has created a serious capacity bottleneck — currently the most prominent market access barrier.

Regulatory Authority

  • Regulatory structure: The EU has no single federal-level medical device approval authority (unlike FDA). Oversight is carried out by each member state's Competent Authority (CA); the European Commission (DG SANTE) sets the overarching regulatory framework.
    • Key member state CAs: Germany's BfArM (Federal Institute for Drugs and Medical Devices), France's ANSM (National Agency for the Safety of Medicines and Health Products), the Netherlands' RIVM/IGJ, Italy's AIFA, Spain's AEMPS
    • Medical Device Coordination Group (MDCG): Coordinates member state CA positions and issues guidance documents
  • Notified Bodies (NB): Third-party conformity assessment bodies designated by member state CAs and recognized by the European Commission. Responsible for conformity assessment of Class IIa and above devices. Currently approximately 42 NBs hold EU MDR designation (sharply reduced from ~80 under MDD). Major NBs include BSI (UK-origin, now operating EU business from Ireland), TÜV SÜD, TÜV Rheinland, SGS, Dekra, and LRQA.
  • Official portals:
  • Key regulations (essential reading):
    • EU MDR 2017/745: Medical Device Regulation, fully applicable from 26 May 2021; replaces MDD 93/42/EEC and AIMDD 90/385/EEC; 123 articles + 17 annexes — the highest-level EU medical device regulation
    • EU IVDR 2017/746: In Vitro Diagnostic Medical Devices Regulation, fully applicable from 26 May 2022; replaces IVDD 98/79/EC
    • MDR Annex I: General Safety and Performance Requirements (GSPR) — manufacturers must satisfy each requirement individually
    • MDR Annex II: Technical Documentation requirements — the structural specification for the core dossier
    • MDR Annex III: Technical Documentation on Post-Market Surveillance
    • MDR Annexes IX–XI: Conformity assessment procedures (various routes)
    • MDR Article 10: General obligations of the manufacturer
    • MDR Article 11: Authorized Representative (EU AR) requirements — core compliance obligation for non-EU manufacturers
    • MDR Article 61: Clinical evaluation requirements
    • MDR Article 120: Transitional provisions (MDD → MDR migration)
    • MEDDEV 2.7/1 Rev.4: Clinical evaluation guidance — while an older document, it remains the de facto benchmark for NB review
    • MDCG 2020-5/2020-6/2021-6 and related guidance series: Specialist guidance on clinical evaluation, PMCF, UDI, software classification, etc.

Device Classification

Local Classification Risk Level FDA Equivalent Typical Products Conformity Assessment Route
Class I Lowest risk FDA Class I Examination gloves, bandages, tongue depressors, sterile device packs Self-declaration (some require NB review for specific aspects)
Class I (sterile/measuring/reusable surgical) Low risk (special sub-class) FDA Class I/II Sterile gauze, measuring devices, surgical scissors NB review required for specific aspects
Class IIa Medium-low risk FDA Class II Syringes, diagnostic ultrasound, hearing aids, contact lenses NB conformity assessment required
Class IIb Medium-high risk FDA Class II/III Ventilators, infusion pumps, orthopedic implants, X-ray machines NB conformity assessment required (more stringent)
Class III Highest risk FDA Class III Cardiac pacemakers, coronary stents, absorbable implants, neurostimulators NB conformity assessment + design examination required

IVD Classification System (EU IVDR 2017/746):

IVDR Class Risk Level Typical Products Conformity Assessment Route
Class A Lowest risk General culture media, blood collection tubes, specimen containers Self-declaration
Class B Low–medium risk General hematology analyzers, biochemistry analyzers NB quality system audit required
Class C Medium–high risk Blood glucose meters, coagulation testing, infectious disease IgG antibody tests NB technical documentation + quality system review required
Class D Highest risk HIV tests, blood typing, HCV testing Full NB review + EU reference laboratory consultation required

Note: Classification rules are detailed in MDR Annex VIII (medical devices) and IVDR Annex VIII (IVDs). Classification disputes may be submitted to member state CAs for a ruling. The classification decision has a decisive impact on all subsequent compliance costs and timelines; a professional classification analysis is strongly recommended early in the project.

Registration Pathway

During the limited-time free period, sign in or register to view the complete medical device country report.